Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Mcph1-deficient mice reveal a role for MCPH1 in otitis media.

PloS one | 2013

Otitis media is a common reason for hearing loss, especially in children. Otitis media is a multifactorial disease and environmental factors, anatomic dysmorphology and genetic predisposition can all contribute to its pathogenesis. However, the reasons for the variable susceptibility to otitis media are elusive. MCPH1 mutations cause primary microcephaly in humans. So far, no hearing impairment has been reported either in the MCPH1 patients or mouse models with Mcph1 deficiency. In this study, Mcph1-deficient (Mcph1(tm1a) (/tm1a) ) mice were produced using embryonic stem cells with a targeted mutation by the Sanger Institute's Mouse Genetics Project. Auditory brainstem response measurements revealed that Mcph1(tm1a) (/tm1a) mice had mild to moderate hearing impairment with around 70% penetrance. We found otitis media with effusion in the hearing-impaired Mcph1(tm1a) (/tm1a) mice by anatomic and histological examinations. Expression of Mcph1 in the epithelial cells of middle ear cavities supported its involvement in the development of otitis media. Other defects of Mcph1(tm1a) (/tm1a) mice included small skull sizes, increased micronuclei in red blood cells, increased B cells and ocular abnormalities. These findings not only recapitulated the defects found in other Mcph1-deficient mice or MCPH1 patients, but also revealed an unexpected phenotype, otitis media with hearing impairment, which suggests Mcph1 is a new gene underlying genetic predisposition to otitis media.

Pubmed ID: 23516444 RIS Download

Research resources used in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: Medical Research Council, United Kingdom
    Id: MC_QA137918
  • Agency: NEI NIH HHS, United States
    Id: R01 EY018213
  • Agency: Cancer Research UK, United Kingdom
    Id: 12401
  • Agency: Medical Research Council, United Kingdom
    Id: G0300212
  • Agency: NEI NIH HHS, United States
    Id: P30 EY019007
  • Agency: Cancer Research UK, United Kingdom
    Id: C20510/A13031
  • Agency: Wellcome Trust, United Kingdom
  • Agency: Cancer Research UK, United Kingdom
    Id: 13031
  • Agency: Wellcome Trust, United Kingdom
    Id: 098051
  • Agency: Wellcome Trust, United Kingdom
    Id: 100669

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Cancer Research UK (tool)

RRID:SCR_004041

Cancer Research UK is the world''s leading charity dedicated to beating cancer through research. We''ve saved millions of lives with our groundbreaking work into preventing, diagnosing and treating cancer. People''s chances of surviving cancer have doubled in the last 40 years, and we''ve been at the heart of that progress. But more than one in three of us will still get cancer at some point. Our vital work, funded entirely by the public, will help ensure that millions more people survive. Our aim is to save lives from cancer. More people are beating cancer than ever before thanks to our work and your support. We work in the areas where we can make the most impact: * Research we support the work of over 4,000 scientists, doctors and nurses across the UK to investigate all aspects of cancer. * Information we work to prevent cancer and help people cope with its effects by providing information for cancer patients and their families, health professionals and the general public. * Influencing public policy we campaign to keep cancer at the top of the health agenda. Cancer Research UK is a registered charity in England and Wales (1089464) and in Scotland (SC041666). Registered as a company limited by guarantee in England & Wales No. 4325234.

View all literature mentions

Sanger Mouse Resources Portal (tool)

RRID:SCR_006239

Database of mouse research resources at Sanger: BACs, targeting vectors, targeted ES cells, mutant mouse lines, and phenotypic data generated from the Institute''''s primary screen. The Wellcome Trust Sanger Institute generates, characterizes, and uses a variety of reagents for mouse genetics research. It also aims to facilitate the distribution of these resources to the external scientific community. Here, you will find unified access to the different resources available from the Institute or its collaborators. The resources include: 129S7 and C57BL6/J bacterial artificial chromosomes (BACs), MICER gene targeting vectors, knock-out first conditional-ready gene targeting vectors, embryonic stem (ES) cells with gene targeted mutations or with retroviral gene trap insertions, mutant mouse lines, and phenotypic data generated from the Institute''''s primary screen.

View all literature mentions

International Mouse Phenotyping Consortium (IMPC) (tool)

RRID:SCR_006158

Center that produces knockout mice and carries out high-throughput phenotyping of each line in order to determine function of every gene in mouse genome. These mice will be preserved in repositories and made available to scientific community representing valuable resource for basic scientific research as well as generating new models for human diseases.

View all literature mentions

C57BL/6N (tool)

RRID:MGI:2159965

laboratory mouse with name C57BL/6N from MGI.

View all literature mentions